NEW YORK (GenomeWeb) – Cowen said today that it has upgraded its rating on Hologic's shares to Outperform from Market Perform, based in part on the investment bank's expectation of "resilient" mid-single-digit or greater than high-single-digit revenue growth for Hologic's molecular diagnostics business.

In a research note, analyst Doug Schenkel said that Cowen's revenue growth expectations were also driven by expected sales for Hologic's new products, and continued mid-single-digit or high-single-digit growth for its surgical business.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.